Trial reportBritish journal of clinical pharmacology2026
Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individuals.
Trial report in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individuals.British journal of clinical pharmacology · 2026Trial
- Drug-drug interaction between ticagrelor and fazamorexant: pharmacokinetic alterations in healthy subjects from a phase I, open-label, fixed-sequence study.BMC pharmacology & toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsFazamorexant is a dual orexin receptor antagonist being developed for the treatment of insomnia. This study aims to determine the dose-exposure-response relationship of single-dose fazamorexant vs. zolpidem in young adult and elderly healthy Chinese volunteers.
methodsThis single-centre, randomized, double-blind, double-dummy, placebo- and active-controlled, 4-period crossover study administered fazamorexant (40 mg/80 mg to young adults; 20 mg/40 mg to the elderly) and zolpidem (10 mg). Pharmacokinetics, pharmacodynamics (primary endpoint: SPV) and safety were assessed.
resultsFollowing a single 40 mg oral dose of fazamorexant in elderly and young adults, the geometric least‑squares mean (GLSM) values for C
conclusionsClinically hypnotic doses of fazamorexant induced less balance, judgement and memory impairment in healthy adults and elderly volunteers compared to the comprehensive suppression of zolpidem on the neurological system. These preliminary results suggest that fazamorexant is a potentially safer drug for insomnia. No age-related pharmacokinetic difference was identified with fazamorexant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.